A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM.
Mariette
X
X
Brouet
J C
JC
Chevret
S
S
Leger
J M
JM
Clavelou
P
P
Pouget
J
J
Vallat
J M
JM
Vial
C
C
D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology*; D011446:Prospective Studies; D016896:Treatment Outcome
D001323:Autoantibodies; D007075:Immunoglobulin M; D016898:Interferon-alpha; D018992:Myelin-Associated Glycoprotein